These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 4054194)
21. Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. McGourty JC; Silas JH; Fleming JJ; McBurney A; Ward JW Clin Pharmacol Ther; 1985 Oct; 38(4):409-13. PubMed ID: 2864157 [TBL] [Abstract][Full Text] [Related]
22. Comparison of two slow-release formulations of metoprolol with conventional metoprolol and atenolol in hypertensive patients. Silas JH; Freestone S; Lennard MS; Ramsay LE Br J Clin Pharmacol; 1985 Oct; 20(4):387-91. PubMed ID: 4074607 [TBL] [Abstract][Full Text] [Related]
23. Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin. Roy SD; Hawes EM; McKay G; Korchinski ED; Midha KK Clin Pharmacol Ther; 1985 Aug; 38(2):128-33. PubMed ID: 4017414 [TBL] [Abstract][Full Text] [Related]
24. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Horai Y; Nakano M; Ishizaki T; Ishikawa K; Zhou HH; Zhou BI; Liao CL; Zhang LM Clin Pharmacol Ther; 1989 Aug; 46(2):198-207. PubMed ID: 2758729 [TBL] [Abstract][Full Text] [Related]
25. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio. Kallio J; Lindberg R; Huupponen R; Iisalo E Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585 [TBL] [Abstract][Full Text] [Related]
26. Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Iyun AO; Lennard MS; Tucker GT; Woods HF Clin Pharmacol Ther; 1986 Oct; 40(4):387-94. PubMed ID: 3757401 [TBL] [Abstract][Full Text] [Related]
27. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine. Gross AS; Phillips AC; Rieutord A; Shenfield GM Br J Clin Pharmacol; 1996 Apr; 41(4):311-7. PubMed ID: 8730977 [TBL] [Abstract][Full Text] [Related]
28. Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype. Lennard MS; Tucker GT; Woods HF; Silas JH; Iyun AO Br J Clin Pharmacol; 1989 May; 27(5):613-6. PubMed ID: 2757883 [TBL] [Abstract][Full Text] [Related]
29. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Siddoway LA; Thompson KA; McAllister CB; Wang T; Wilkinson GR; Roden DM; Woosley RL Circulation; 1987 Apr; 75(4):785-91. PubMed ID: 3829342 [TBL] [Abstract][Full Text] [Related]
30. Oxidation phenotype--a major determinant of metoprolol metabolism and response. Lennard MS; Silas JH; Freestone S; Ramsay LE; Tucker GT; Woods HF N Engl J Med; 1982 Dec; 307(25):1558-60. PubMed ID: 7144837 [No Abstract] [Full Text] [Related]
31. Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance. Smith RL Eur J Clin Pharmacol; 1985; 28 Suppl():77-84. PubMed ID: 2865154 [TBL] [Abstract][Full Text] [Related]
32. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657 [TBL] [Abstract][Full Text] [Related]
33. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. Seeringer A; Brockmöller J; Bauer S; Kirchheiner J Eur J Clin Pharmacol; 2008 Sep; 64(9):883-8. PubMed ID: 18545991 [TBL] [Abstract][Full Text] [Related]
34. Oxidation phenotype and the metabolism and action of beta-blockers. Lennard MS Klin Wochenschr; 1985 Apr; 63(7):285-92. PubMed ID: 2860267 [TBL] [Abstract][Full Text] [Related]
35. [Determination of the oxidation phenotype in the Czechoslovak population using metoprolol]. Ulc I; Ulc J; Cepeláková H Cas Lek Cesk; 1990 Feb; 129(8):244-6. PubMed ID: 2331742 [TBL] [Abstract][Full Text] [Related]
36. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329 [TBL] [Abstract][Full Text] [Related]
37. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. Brynne N; Böttiger Y; Hallén B; Bertilsson L Br J Clin Pharmacol; 1999 Feb; 47(2):145-50. PubMed ID: 10190648 [TBL] [Abstract][Full Text] [Related]
38. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation. Dayer P; Leemann T; Küpfer A; Kronbach T; Meyer UA Eur J Clin Pharmacol; 1986; 31(3):313-8. PubMed ID: 2878813 [TBL] [Abstract][Full Text] [Related]
39. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Bijl MJ; Visser LE; van Schaik RH; Kors JA; Witteman JC; Hofman A; Vulto AG; van Gelder T; Stricker BH Clin Pharmacol Ther; 2009 Jan; 85(1):45-50. PubMed ID: 18784654 [TBL] [Abstract][Full Text] [Related]
40. A comparison of 100 mg atenolol and 100 mg metoprolol once a day at rest and during exercise in hypertensives. Nilsson OR; Atterhög JH; Castenfors J; Jorfelt L; Karlberg BE; Thulin T; Tolagen K; Wettre S; Ohman KP Acta Med Scand; 1984; 216(3):301-7. PubMed ID: 6388253 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]